Malhan, SimtenGoksel, TuncayKaradurmus, NuriKavakli, KuthanSavas, RecepSendur, Mehmet Ali NihatSimsek, Gokcen2025-02-182025-02-182024MALHAN, S., GÖKSEL, T., KARADURMUŞ, N., KAVAKLI, K., SAVAŞ, R., ŞENDUR, M. A. N., & ŞIMŞEK, G. (2025). The Cost-effectiveness of National Lung Cancer Screening in Türkiye. TURKISH JOURNAL OF ONCOLOGY, 1(1).1300-7467https://doi.org/10.5505/tjo.2024.4464https://hdl.handle.net/11454/116075OBJECTIVE The aim of this study is to analyze the cost-effectiveness of the national lung cancer screening program in T & uuml;rkiye. METHODS In this cost-effectiveness model, the most likely protocol to be used after implementing a lung cancer survey for T & uuml;rkiye, the NELSON protocol, was used to make a comparison with the "no screening" case. This protocol involves individuals screened using low-dose computed tomography (LDCT). The model is anticipated to simulate 14 screening rounds, assuming an age range of 50-74 for lung cancer and 58 years for the screening program participants. The main outputs of the model were total life years gained (LYG), quality-adjusted life years (QALYs) gained in the screening arm, and the incremental cost-effectiveness ratio (ICER). RESULTS The analyses revealed a total QALY gained in the screening arm of 12,465,801 vs. a QALY gained of 12,149,148 in the comparator no screening arm. The incremental QALY value was estimated to be 316,654. The total LYG were 15,954,511 and 15,370,671 in the screening and no screening arms, respectively, resulting in an incremental LYG of 583,840. With lung cancer screening, stage III and IV cancer were identified in earlier phases in 13,636 cases. Prevented early deaths were 7,576. For the lung cancer screening program, the cost per QALY is $571, and the cost per LYG is $310. CONCLUSION Based on the results, implementation of the national lung cancer screening program was found to be very cost-effective for T & uuml;rkiye.en10.5505/tjo.2024.4464info:eu-repo/semantics/closedAccessLife year gainslung cancerlung cancer screeningNELSONQALYsArticleDec113Q4